- Home
- MRLN vs BLFS Comparison
MRLN vs BLFS Comparison
Compare MRLN & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | BLFS |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.1M | 923.5M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MRLN | BLFS |
|---|---|---|
| Price | $6.55 | $23.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $25.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.3M | 366.8K |
| Earning Date | 10-28-2021 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | N/A | $19.73 |
| Revenue Next Year | N/A | $17.82 |
| P/E Ratio | ★ N/A | $1,146.75 |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $5.88 | $17.86 |
| 52 Week High | $17.00 | $29.57 |
Technical Indicators
Market Signals| Indicator | MRLN | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 63.38 |
| Support Level | $6.22 | $21.35 |
| Resistance Level | $17.00 | $26.14 |
| Average True Range (ATR) | 0.99 | 1.05 |
| MACD | -0.31 | 0.13 |
| Stochastic Oscillator | 15.68 | 86.02 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.